Clinical Trials Now Enrolling


NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA

A  Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.

Learn More

Trial Eligibility

Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.

Trial Screening

NIRAPARIB FOR RECURRENT GLIOMA (GRADES II-IV)

A  Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss.

Learn More

Trial Eligibility

Visit ClinicalTrials.gov or use NCT identifier NCT05076513 to view inclusion criteria and additional study details.

Trial Screening

SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA

A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.

Trial Screening

PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04614909 to view inclusion criteria and additional study details.

Trial Screening

INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA

A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.

Trial Screening Physician Information


ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA

A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration

Learn More

Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.

Trial Screening Physician Information


RIBOCICLIB FOR RECURRENT GLIOBLASTOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.

Trial Screening

RIBOCICLIB FOR RECURRENT MENINGIOMA

A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT02933736  to view inclusion criteria and additional study details.

Trial Screening

RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT HIGH-GRADE GLIOMA

A Phase 0/2 study of ribociclib in combination with everolimus in preoperative Rb-intact recurrent high-grade glioma patients scheduled for resection


Am I eligible?

Visit ClinicalTrials.gov or use NCT identifier NCT03834740  to view inclusion criteria and additional study details.

Trial Screening